Stoke Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STOK and other ETFs, options, and stocks.

About STOK

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. 

CEO
Ian Frederick Smith
CEOIan Frederick Smith
Employees
170
Employees170
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2014
Founded2014
Employees
170
Employees170

STOK Key Statistics

Market cap
2.09B
Market cap2.09B
Price-Earnings ratio
-9.58
Price-Earnings ratio-9.58
Dividend yield
Dividend yield
Average volume
907.65K
Average volume907.65K
High today
$32.41
High today$32.41
Low today
$32.30
Low today$32.30
Open price
$32.29
Open price$32.29
Volume
307.00
Volume307.00
52 Week high
$40.22
52 Week high$40.22
52 Week low
$18.00
52 Week low$18.00

Stock Snapshot

With a market cap of 2.09B, Stoke Therapeutics(STOK) trades at $32.41. The stock has a price-to-earnings ratio of -9.58.

On 2026-08-25, Stoke Therapeutics(STOK) stock moved within a range of $32.30 to $32.41. With shares now at $32.41, the stock is trading +0.3% above its intraday low and 0.0% below the session's peak.

Trading volume for Stoke Therapeutics(STOK) stock has reached 307, versus its average volume of 907.65K.

The stock's 52-week range extends from a low of $18.00 to a high of $40.22.

The stock's 52-week range extends from a low of $18.00 to a high of $40.22.

STOK News

TipRanks 4d
Stoke Therapeutics reinstated with an Overweight at JPMorgan

JPMorgan analyst Jessica Fye reinstated coverage of Stoke Therapeutics (STOK) with an Overweight rating and $40 price target The firm sees a high probability of...

Simply Wall St 5d
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics?

Stoke Therapeutics recently reported that its Phase III EMPEROR trial of zorevunersen in Dravet syndrome exceeded its 150-patient enrollment goal, reaching 162...

Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics?

Analyst ratings

100%

of 14 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own STOK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.